Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer Christina H. YeonMark D. Pegram OriginalPaper Pages: 391 - 409
Novel therapy in multiple myeloma Agustin AvilésNatividad NeriJudith Huerta-Guzmán OriginalPaper Pages: 411 - 415
Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists Doris M. BenbrookScott A. KamelleK. Darrell Berlin OriginalPaper Pages: 417 - 428
Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer J. H. BeumerJ. M. Rademaker-LakhaiJ. H. M. Schellens OriginalPaper Pages: 429 - 436
An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin H. HirteD. Stewartand L. Seymour OriginalPaper Pages: 437 - 443
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130 Karen A. GelmonKarl BelangerLesley Seymour OriginalPaper Pages: 445 - 453
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies Eric X. ChenGerald BatistLesley Seymour OriginalPaper Pages: 455 - 465
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer Ranjana AdvaniBert L. LumBranimir I. Sikic OriginalPaper Pages: 467 - 477
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer Jaffer A. AjaniChris TakimotoRobert De Jager OriginalPaper Pages: 479 - 484
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study John S. MacdonaldSheryl McCoyJames L. Abbruzzese OriginalPaper Pages: 485 - 487
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers Hedy L. KindlerPeter K. TothyEverett E. Vokes OriginalPaper Pages: 489 - 493
Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial Evanthia GalanisJan C. BucknerSteven A. Kuross OriginalPaper Pages: 495 - 503